A Src/Abl kinase inhibitor, bosutinib, downregulates and inhibits PARP enzyme and sensitizes cells to the DNA damaging agents

BALLAR KIRMIZIBAYRAK P., İLHAN R., Yilmaz S., Gunal S., ERBAYKENT TEPEDELEN B.

TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, vol.43, no.2, pp.101-109, 2018 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 43 Issue: 2
  • Publication Date: 2018
  • Doi Number: 10.1515/tjb-2017-0095
  • Journal Name: TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.101-109
  • Keywords: PARP inhibitor, PARylation, Bosutinib, Multi-kinase inhibitor, Chemosensitizer, POLY(ADP-RIBOSE) POLYMERASE-1 INHIBITOR, SKI-606 BOSUTINIB, BREAST-CANCER, GROWTH, DEATH, ACTIVATION, PROSTATE, INVASION, PATHWAY, STRESS
  • Bursa Uludag University Affiliated: Yes

Abstract

Background: Poly(ADP-ribosyl)ation (PARylation) catalyzed mainly by PARP1 is a highly regulated posttranslational modification associated with several pathways in cellular physiology and genotoxic deoxyribonucleic acid (DNA) damage response. PAR polymers and PARP enzyme function in DNA integrity maintenance and several PARP inhibitors have entered clinical phase studies for cancer therapies.